PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Cash & equivalents declining -16.72% while Biotechnology shows -10.51% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -9.31%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-19.08%
Current assets growth ≥ 1.5x the Biotechnology median of -7.70%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-14.24%
PP&E growth ≥ 1.5x the Biotechnology median of -0.17%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
≥ 1.5x the Biotechnology median of -0.42%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
≥ 1.5x the Biotechnology median of -4.83%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-4.20%
Payables growth above 1.5x Biotechnology median of -0.63%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
18.79%
Below half Biotechnology median of -0.59%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Below half Biotechnology median of -1.21%. Joel Greenblatt sees a much lower liability expansion vs. peers.
2.42%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-5.90%
1.25-1.5x Biotechnology median of -4.08%. Mohnish Pabrai notes above-average reinvested earnings.
-12.27%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
≥ 1.5x Biotechnology median of -5.13%. Joel Greenblatt sees stronger equity growth vs. peers.
-19.02%
≥ 1.5x Biotechnology median of -4.83%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Above 1.5x Biotechnology median 9.96%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.